106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2019 All rights reserved
ASCOCOL1943a
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncology
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket guide does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
gastrointestinal-cancer-guidelines. Copyright © 2019 by American Society of Clinical Oncology.
All rights reserved.
Abbreviations
CAPOX, capecitabine and oxaliplatin; FOLFOX, infusional 5-FU, leucovorin and oxaliplatin
Source
Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L,
Mahmoud N, Meyerhardt J, Morris AM, Garcia ER, You YN, Baxter N. Duration of
Oxaliplatin-containing Adjuvant erapy for Stage III Colon Cancer: ASCO Clinical Practice
Guideline. J Clin Oncol. 2019 April 15. doi: 10.1200/JCO.19.00281
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
CB
Consensus-
based
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets,
frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/gastrointestinal-cancer-guidelines
